The chronic pain market in America is vast, expensive, and—depending on whom you ask—ripe for disruption or hopelessly complex. PainDrainer, a Swedish digital therapeutics company working from a life sciences hub in Lund, is placing a measured wager on the former.
The company just closed a 6.0 million SEK share issue in the second quarter of 2026, announced May 12 on its website and company LinkedIn. Returning investors Almi Invest and Tramontane Invest anchored the round. Not a massive haul by Silicon Valley standards, perhaps, but for a team of roughly 2–10 employees navigating the labyrinthine U.S. healthcare reimbursement system, it's capital earmarked for traction, not spectacle.
Founded in 2018 by Professor Carl Borrebaeck, Dr. Maria Rosén Klement, and IT specialist Göran Barkfors, PainDrainer has been steadily building both a clinical and consumer footprint. The company initially raised €600,000 in angel financing back in April 2019, followed by a 12.5 million SEK round in December 2021 led by Almi Invest, and an oversubscribed 9.5 million SEK raise in March 2025. The latest round brings the tally to multiple millions raised across several years—a slow-burn approach in an industry where patience, regulatory savvy, and clinical validation matter as much as venture momentum.
Navigating the RTM Gold Rush
What PainDrainer is selling, fundamentally, is a blend of clinical legitimacy and reimbursement-ready infrastructure. Its flagship product, the PD Care System, sits at the intersection of chronic pain management and Remote Therapeutic Monitoring—a category that gained regulatory teeth when the Centers for Medicare & Medicaid Services introduced RTM billing codes in 2022.
The platform is registered with the FDA as a Class I (510(k)-exempt) device under product code OUG (Medical Device Data System), with a GUDID listing that went live in November 2025. It also carries CE certification in Europe and secured a European patent grant (EP 4186064 B1) in October 2024. On paper, the regulatory ducks are in a row.
The company's U.S. website positions the platform for healthcare providers working within the RTM reimbursement framework—a suite of CPT codes that, in theory, allow clinics to get paid for remotely monitoring patients' pain levels and therapeutic adherence. The target population is sizable: CDC data from 2023 estimates that roughly 25% of U.S. adults live with chronic pain. That's tens of millions of people, many of whom cycle through opioid prescriptions, physical therapy, and a constellation of specialists.
Whether RTM becomes a genuine revenue stream for overburdened primary care practices, or just another administrative burden dressed up as innovation, remains an open question among industry observers. PainDrainer is betting on the former.
Clinical Validation Meets Consumer Play
A 2023 multicenter study published in Pain Medicine—conducted at Newton-Wellesley Hospital and Weill Cornell Medical Center—provided some clinical validation for the platform's AI-powered self-management tools. More recently, on May 14, 2026, PainDrainer announced that a health-economic study analyzing the platform had been peer-reviewed and published in the same journal. Collaborators on that study included researchers from the Institute for Health Economics at Lund University, lending academic heft to the company's claims about cost-effectiveness.
But PainDrainer isn't limiting itself to the clinical side of the fence. In May 2026, the company launched Relivra, a consumer-facing AI pain support companion app that operates independently of its medical device. Relivra runs on a freemium model with subscription tiers and is explicitly marketed as a wellness tool, not a medical device—a strategic hedge that sidesteps FDA oversight while capturing a broader consumer audience.
It's a dual-track strategy that feels both pragmatic and slightly hedged. If the RTM reimbursement world proves slower to materialize than hoped, the consumer wellness app offers a parallel revenue stream. If the clinical side takes off, Relivra becomes a brand-building on-ramp.
The Road Ahead
CEO Erik Frick, who joined in 2022 from a background in digital services commercialization at Resurs Bank, appears to be steering the company toward measured U.S. expansion. Based out of Medicon Village—a cluster of biotech and medtech companies in Lund—PainDrainer operates with the lean profile typical of Nordic health tech ventures: small team, targeted approach, regulatory diligence.
The Q2 2026 capital will likely fund continued efforts to onboard U.S. clinics and scale the consumer app, though the company didn't disclose specific use-of-funds details in its announcement. For observers tracking the slow evolution of non-pharmacologic pain solutions and the halting adoption of value-based care models, PainDrainer offers a case study worth watching.
The company is navigating a market defined by high stakes, entrenched interests, and genuine human suffering. Whether its blend of AI, regulatory compliance, and dual-market strategy translates into sustainable business remains to be seen. But in a sector where innovation often collides with reimbursement realities, PainDrainer's incremental, evidence-backed approach may prove more durable than the usual Silicon Valley sprint.
